Gleneagles Hospital Chennai Achieves Complete Remission in Rare Brain Lymphoma Using India's Indigenous CAR-T Therapy NexCAR19
核心洞察
A 49-year-old patient with primary central nervous system lymphoma (搜索) (PCNSL) achieved complete remission after receiving NexCAR19, India's indigenous CAR-T cell therapy, at Gleneagles Hospital Chennai (搜索).
The patient's disease had progressed despite high-dose chemotherapy, radiotherapy, and oral targeted therapy before the CAR-T intervention was pursued.
Following CAR-T infusion, the patient developed serious treatment-related complications but recovered with support from a multidisciplinary team spanning oncology, hematology, infectious diseases, and intensive care.
A 49-year-old patient from Andhra Pradesh diagnosed with a rare and aggressive form of brain lymphoma has achieved complete remission following treatment with NexCAR19 (talicabtagene autoleucel (搜索)), India's indigenous CAR-T cell therapy, at Gleneagles Hospital Chennai (搜索). The case marks a significant advancement in the application of domestically developed cell therapy for primary central nervous system lymphoma (搜索) (PCNSL), a life-threatening malignancy with notoriously limited treatment options.
The patient, Karnan Madhusudhanan, initially presented with persistent headache, giddiness, difficulty walking, and weakness in the left arm and leg. Detailed investigations confirmed the diagnosis of PCNSL, a rare brain lymphoma that poses substantial therapeutic challenges.
Disease Progression Despite Standard Therapies
The patient's clinical course was marked by refractory disease. He initially received high-dose chemotherapy, the standard first-line treatment for PCNSL. However, the lymphoma continued to progress after four cycles. The clinical team subsequently administered radiotherapy combined with chemotherapy and oral targeted therapy as a bridging strategy. Despite these interventions, the disease remained resistant to treatment.
At this juncture, the multidisciplinary team at Gleneagles Hospital Chennai (搜索), led by Dr. V. Arun Ramanan, Clinical Lead and Senior Consultant in Medical Oncology, discussed advanced therapeutic options with the patient and his family. The team proposed treatment with NexCAR19, an indigenous CAR-T cell therapy developed in India.
CAR-T Cell Therapy: Mechanism and Administration
The treatment protocol involved collecting the patient's immune cells through a specialized procedure called leukapheresis. These cells were then genetically modified to recognize and attack lymphoma cells, and subsequently reinfused into the patient as CAR-T cells. The engineered cells are designed to identify, engage, and eliminate cancer cells expressing the CD19 antigen.
Complication Management and Recovery
Following the CAR-T cell infusion, the patient developed several serious health complications associated with CAR-T cell therapy. A dedicated multidisciplinary team comprising specialists from medical oncology, hematology, infectious diseases, intensive care, and nursing provided comprehensive supportive care. After approximately one month of intensive treatment, the patient recovered sufficiently and was discharged.
According to Dr. Arun Ramanan, the patient has now recovered fully and is set to lead a normal life. S. Niranjani, Chief Operating Officer and Hospital Head of Gleneagles Hospital, and R.Y. Bharath Kanth Reddy, Chief Executive Officer of the Chennai and Hyderabad clusters, also acknowledged the clinical achievement.
The successful application of NexCAR19 in this challenging case underscores the potential of indigenous CAR-T platforms to address complex hematologic malignancies, including those with central nervous system involvement, where conventional therapies have failed.